To evaluate whether VEGF expression might modulate the antigen-presenting capacity of tumor cells, we first checked the cell surface expression of MHC class I, class II, B7.1, and ICAM-1 on transfectants by FACS analysis and found no difference between transfectants and control cells (data not shown). Here, ICAM1 is linked to neoplasm.